Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: A one-year prospective trial

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 9, 2010, Pages 1550-1555

  Kuroda, Hidekatsu ^a   Ushio, Akira ^a   Miyamoto, Yasuhiro ^a   Sawara, Kei ^a   Oikawa, Kanta ^a   Kasai, Kazuhiro ^a   Endo, Ryujin ^a   Takikawa, Yasuhiro ^a   Kato, Akinobu ^b   Suzuki, Kazuyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b Morioka Municipal Hospital   (Japan)

Author keywords

branched chain amino acid; hepatocellular carcinoma; indirect calorimetry; liver cirrhosis; malnutrition; quality of life; radiofrequency ablation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; AMINOLEBAN EN; BILIRUBIN; BIOLOGICAL MARKER; BRANCHED CHAIN AMINO ACID; CARBOHYDRATE; FAT; GLUCOSE; LECTIN; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; ECHOGRAPHY; ENERGY METABOLISM; EVENT FREE SURVIVAL; FATALITY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RESPIRATORY QUOTIENT; SCORING SYSTEM; SHORT FORM 8; SURVIVAL RATE;

EID: 77956024629     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06306.x     Document Type: Article

References (30)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999 340 : 745 750.
2. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998 351 : 214 215.
3. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997 350 : 1142 1143.
4. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 1987 47 : 4967 4972.
5. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996 334 : 693 699.
6. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann. Surg. 2002 235 : 373 382.
7. Tsuzuki T, Sugioka A, Ueda M et al. Hepatic resection for hepatocellular carcinoma. Surgery 1990 107 : 511 520.
8. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999 210 : 655 661.
9. Rossi S, Di Stasi M, Buscarini E et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am. J. Roentgenol. 1996 167 : 759 768.
10. Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002 62 (Suppl. 1 64 8.
11. Balsells J, Charco R, Lazaro JL et al. Resection of hepatocellular carcinoma in patients with cirrhosis. Br. J. Surg. 1996 83 : 758 761.
12. Kudo M. Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology 2008 75 (Suppl. 1 30 41.
13. Kuroda H, Kasai K, Kakisaka K et al. Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma. Hepatol. Res. 2010 in press).
14. Muto Y, Sato S, Watanabe A et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin. Gastroenterol. Hepatol. 2005 3 : 705 713.
15. Moriwaki H, Shiraki M, Fukushima H et al. Long-term outcome of branched-chain amino acid treatment in patients with liver cirrhosis. Hepatol. Res. 2008 38 : S102 6.
16. Suzuki K, Kato A, Iwai M. Branched-chain amino acid treatment in patients with liver cirrhosis. Hepatol. Res. 2004 30S : 25 9.
17. Muto Y, Sato S, Watanabe A et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol. Res. 2006 35 : 204 214.
18. Poon RT, Yu WC, Fan ST, Wong J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment. Pharmacol. Ther. 2004 19 : 779 788.
19. Lam VW, Poon RT. Role of branched-chain amino acids in management of cirrhosis and hepatocellular carcinoma. Hepatol. Res. 2008 38 : S107 15.
20. Turner-Bowker DM, Bayliss MS, Ware JE Jr., Kosinski M. Usefulness of the SF-8 Health Survey for comparing the impact of migraine and other conditions. Qual. Life Res. 2003 12 : 1003 1012.
21. Ware JE, Kosinski M, Dewey JE, Gandek B. How to Score and Interpret Single-Item Healthstatus Measures. A Manual for Users of the SF-8TM Health Survey. Lincoln, RI : QualityMetric Inc., 2001.
22. Plauth M, Merli M, Kondrup J, Weimann A, Ferenci P, Muller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. Clin. Nutr. 1997 16 : 43 55.
23. Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem. Biophys. Res. Commun. 2004 313 : 405 409.
24. Marchesini G, Bianchi G, Merli M et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003 124 : 1792 1801.
25. Koike Y, Yoshida H, Shiina S et al. Changes in hepatic functional reserve after percutaneous tumor ablation for hepatocellular carcinoma: long-term follow up for 227 consecutive patients with a single lesion. Hepatol. Int. 2007 1 : 295 301.
26. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann. Surg. 2000 232 : 381 391.
27. Koike Y, Shiratori Y, Sato S et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000 32 : 1216 1223.
28. Pompili M, Rapaccini GL, de Luca F et al. Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. Cancer 1997 79 : 1501 1508.
29. Okabayashi T, Nishimori I, Sugimoto T et al. The benefit of the supplementation of perioperative branched-chain amino acids in patients with surgical management for hepatocellular carcinoma: a preliminary study. Dig. Dis. Sci. 2008 53 : 204 209.
30. Takeshita S, Ichikawa T, Nakao K et al. A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma. Nutr. Res. 2009 29 : 89 93.